Overview
Human papillomavirus (HPV)-associated adenocarcinoma refers to cancers of the gynecologic tract that are caused by persistent infection with oncogenic HPV types. These cancers can arise in the cervix, vagina, or vulva.Management
Prophylactic HPV vaccination is recommended by many clinicians for patients diagnosed with HPV-related gynecologic cancers, either at the time of diagnosis or after treatment 1.
The rationale for vaccination in this setting is based on the potential to reduce the risk of future HPV-related diseases, drawing parallels from data on HPV vaccination after treatment of pre-invasive disease 1.
Physicians should be aware of national catch-up vaccination programs and counsel patients on vaccine efficacy based on age 1.Key Recommendations
Many clinicians recommend prophylactic HPV vaccination for patients diagnosed with HPV-related gynecologic cancers at the time of diagnosis or after treatment 1. (Evidence: Expert opinion)
Physicians should be aware of catch-up HPV vaccination programs and counsel patients on vaccine efficacy according to their age 1. (Evidence: Expert opinion)
Currently, no evidence supports the use of prophylactic HPV vaccine in patients diagnosed with HPV-related gynecologic cancers 1. (Evidence: Expert opinion)References
1 Bizzarri N, Kyrgiou M, De Vincenzo R, Zapardiel I, Razumova Z, Taumberger N et al.. Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2025. link